Repurposing drugs for the management of COVID-19
Jacopo CusinatoDepartment of Medicine, Surgery and Neuroscience, University of Siena, Siena, ItalyYlenia CauDepartment of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Hospital Pharmacy School, Florence, ItalyAnna Maria CalvaniAOU Anna Meyer Children's University Hospital, Hospital Pharmacy, AOU Anna Meyer Children’s University Hospital, Florence, ItalyMattia MoriDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy
2020en
ABI
Аннотация
: Drug repurposing proved highly successful in response to the current pandemic, with remdesivir becoming the first specific antiviral drug approved for the treatment of COVID-19. In parallel, a number of drugs such as corticosteroids and low molecular weight heparin (LMWH) are used to treat hospitalized COVID-19 patients, while clinical testing of additional therapeutic options is ongoing. It is reasonably expected that these research efforts will deliver optimized and specific therapeutic tools that will increase the preparedness of health systems to possible future epidemics.
Перевод пока недоступен
Идентификаторы
Цитирования и источники
Цитирований: 3Использованных источников: 0